Literature DB >> 26219596

Recombinant tissue-type plasminogen activator transiently enhances blood-brain barrier permeability during cerebral ischemia through vascular endothelial growth factor-mediated endothelial endocytosis in mice.

Yasuhiro Suzuki1,2, Nobuo Nagai3, Kasumi Yamakawa2, Yoshinori Muranaka4, Kazuya Hokamura2, Kazuo Umemura2.   

Abstract

Recombinant tissue-type plasminogen activator (rt-PA) modulates cerebrovascular permeability and exacerbates brain injury in ischemic stroke, but its mechanisms remain unclear. We studied the involvement of vascular endothelial growth factor (VEGF)-mediated endocytosis in the increase of blood-brain barrier (BBB) permeability potentiated by rt-PA after ischemic stroke. The rt-PA treatment at 4 hours after middle cerebral artery occlusion induced a transient increase in BBB permeability after ischemic stroke in mice, which was suppressed by antagonists of either low-density lipoprotein receptor families (LDLRs) or VEGF receptor-2 (VEGFR-2). In immortalized bEnd.3 endothelial cells, rt-PA treatment upregulated VEGF expression and VEGFR-2 phosphorylation under ischemic conditions in an LDLR-dependent manner. In addition, rt-PA treatment increased endocytosis and transcellular transport in bEnd.3 monolayers under ischemic conditions, which were suppressed by the inhibition of LDLRs, VEGF, or VEGFR-2. The rt-PA treatment also increased the endocytosis of endothelial cells in the ischemic brain region after stroke in mice. These findings indicate that rt-PA increased BBB permeability via induction of VEGF, which at least partially mediates subsequent increase in endothelial endocytosis. Therefore, inhibition of VEGF induction may have beneficial effects after thrombolytic therapy with rt-PA treatment after stroke.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26219596      PMCID: PMC4671124          DOI: 10.1038/jcbfm.2015.167

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  40 in total

Review 1.  LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies.

Authors:  Anna P Lillis; Lauren B Van Duyn; Joanne E Murphy-Ullrich; Dudley K Strickland
Journal:  Physiol Rev       Date:  2008-07       Impact factor: 37.312

2.  Human vascular permeability factor. Isolation from U937 cells.

Authors:  D T Connolly; J V Olander; D Heuvelman; R Nelson; R Monsell; N Siegel; B L Haymore; R Leimgruber; J Feder
Journal:  J Biol Chem       Date:  1989-11-25       Impact factor: 5.157

Review 3.  Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling.

Authors:  Sergio Rey; Gregg L Semenza
Journal:  Cardiovasc Res       Date:  2010-02-17       Impact factor: 10.787

4.  Tissue-type plasminogen activator (t-PA) induces stromelysin-1 (MMP-3) in endothelial cells through activation of lipoprotein receptor-related protein.

Authors:  Yasuhiro Suzuki; Nobuo Nagai; Kasumi Yamakawa; Junichi Kawakami; H Roger Lijnen; Kazuo Umemura
Journal:  Blood       Date:  2009-07-16       Impact factor: 22.113

Review 5.  HIF-1: upstream and downstream of cancer metabolism.

Authors:  Gregg L Semenza
Journal:  Curr Opin Genet Dev       Date:  2009-11-26       Impact factor: 5.578

6.  Laboratory monitoring of hemostasis during thrombolytic therapy with recombinant human tissue-type plasminogen activator.

Authors:  H D Garabedian; H K Gold; R C Leinbach; T Yasuda; J A Johns; D Thornton; D Collen
Journal:  Thromb Res       Date:  1988-04-01       Impact factor: 3.944

7.  Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells.

Authors:  A Namiki; E Brogi; M Kearney; E A Kim; T Wu; T Couffinhal; L Varticovski; J M Isner
Journal:  J Biol Chem       Date:  1995-12-29       Impact factor: 5.157

8.  Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator.

Authors:  G Bu; S Williams; D K Strickland; A L Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

9.  Characterization of the murine plasma fibrinolytic system.

Authors:  H R Lijnen; B van Hoef; V Beelen; D Collen
Journal:  Eur J Biochem       Date:  1994-09-15

10.  Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration.

Authors:  M Clauss; M Gerlach; H Gerlach; J Brett; F Wang; P C Familletti; Y C Pan; J V Olander; D T Connolly; D Stern
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

View more
  12 in total

1.  Cryoprecipitate augments the global transduction of the adeno-associated virus serotype 9 after a systemic administration.

Authors:  Zheng Chai; Xintao Zhang; Kelly Michelle Rigsbee; Mei Wang; Richard Jude Samulski; Chengwen Li
Journal:  J Control Release       Date:  2018-08-11       Impact factor: 9.776

2.  Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype.

Authors:  Shorena Janelidze; Joakim Hertze; Katarina Nägga; Karin Nilsson; Christer Nilsson; Malin Wennström; Danielle van Westen; Kaj Blennow; Henrik Zetterberg; Oskar Hansson
Journal:  Neurobiol Aging       Date:  2016-12-05       Impact factor: 4.673

Review 3.  Neurovascular Unit Dysfunction and Blood-Brain Barrier Hyperpermeability Contribute to Schizophrenia Neurobiology: A Theoretical Integration of Clinical and Experimental Evidence.

Authors:  Souhel Najjar; Silky Pahlajani; Virginia De Sanctis; Joel N H Stern; Amanda Najjar; Derek Chong
Journal:  Front Psychiatry       Date:  2017-05-23       Impact factor: 4.157

4.  Isoflurane preconditioning inhibits the effects of tissue-type plasminogen activator on brain endothelial cell in an in vitro model of ischemic stroke.

Authors:  So Yeong Cheon; So Yeon Kim; Eun Hee Kam; Jae Hoon Lee; Jeong Min Kim; Eun Jung Kim; Tae Whan Kim; Bon-Nyeo Koo
Journal:  Int J Med Sci       Date:  2017-04-08       Impact factor: 3.738

5.  Tissue-type plasminogen activator exerts EGF-like chemokinetic effects on oligodendrocytes in white matter (re)myelination.

Authors:  Camille Leonetti; Richard Macrez; Mathilde Pruvost; Yannick Hommet; Jérémie Bronsard; Antoine Fournier; Maxime Perrigault; Isabel Machin; Denis Vivien; Diego Clemente; Fernando De Castro; Eric Maubert; Fabian Docagne
Journal:  Mol Neurodegener       Date:  2017-02-23       Impact factor: 14.195

6.  Role of the S1P pathway and inhibition by fingolimod in preventing hemorrhagic transformation after stroke.

Authors:  Angélica Salas-Perdomo; Francesc Miró-Mur; Mattia Gallizioli; Vanessa H Brait; Carles Justicia; Anja Meissner; Xabier Urra; Angel Chamorro; Anna M Planas
Journal:  Sci Rep       Date:  2019-06-05       Impact factor: 4.379

Review 7.  A Review of the Mechanisms of Blood-Brain Barrier Permeability by Tissue-Type Plasminogen Activator Treatment for Cerebral Ischemia.

Authors:  Yasuhiro Suzuki; Nobuo Nagai; Kazuo Umemura
Journal:  Front Cell Neurosci       Date:  2016-01-25       Impact factor: 5.505

8.  LDL receptor blockade reduces mortality in a mouse model of ischaemic stroke without improving tissue-type plasminogen activator-induced brain haemorrhage: towards pre-clinical simulation of symptomatic ICH.

Authors:  Be'eri Niego; Brad R S Broughton; Heidi Ho; Christopher G Sobey; Robert L Medcalf
Journal:  Fluids Barriers CNS       Date:  2017-11-21

Review 9.  The peripheral immune response after stroke-A double edge sword for blood-brain barrier integrity.

Authors:  Yan Li; Zi-Yu Zhu; Ting-Ting Huang; Yu-Xi Zhou; Xin Wang; Li-Qun Yang; Zeng-Ai Chen; Wei-Feng Yu; Pei-Ying Li
Journal:  CNS Neurosci Ther       Date:  2018-11-01       Impact factor: 5.243

10.  Rosiglitazone ameliorates tissue plasminogen activator-induced brain hemorrhage after stroke.

Authors:  Yan Li; Zi-Yu Zhu; Bing-Wei Lu; Ting-Ting Huang; Yue-Man Zhang; Na-Ying Zhou; Wei Xuan; Zeng-Ai Chen; Da-Xiang Wen; Wei-Feng Yu; Pei-Ying Li
Journal:  CNS Neurosci Ther       Date:  2019-11-22       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.